Dear NCCN Guidelines Panel for Non-Small Cell Lung Cancer,

Request:

- Please consider for inclusion into the guideline the results of the randomized Phase 3 IMpower130 trial designed to evaluate Tecentriq® (atezolizumab) plus carboplatin and nab-paclitaxel for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC).

Rationale:

- At a median follow-up of 19 months, Tecentriq plus carboplatin and nab-paclitaxel met both co-primary endpoints of investigator-assessed progression-free survival and overall survival compared to carboplatin plus nab-paclitaxel for the first-line treatment of patients with metastatic non-squamous NSCLC in the ITT-wild type population (randomized patients excluding those with EGFR or ALK genetic alteration).
- The safety profile of Tecentriq plus carboplatin and nab-paclitaxel was consistent with the known safety risks of the individual medicines with no new safety signals observed.

FDA Clearance:

- Tecentriq plus carboplatin and nab-paclitaxel is not FDA-approved for the treatment of patients with metastatic non-squamous NSCLC. Please refer to the product prescribing information for the full FDA-approved indications and safety information, available at: https://www.gene.com/medical-professionals/medicines/tecentriq

Any references supplied to you are protected under U.S. Copyright Law (Title 17, U.S. Code). No further reproduction is permitted.

Thank you for your consideration and I hope this information is helpful to you. If you have any questions, please contact us at the phone number and email provided above.

Respectfully submitted,

Jordana Wollmann, PharmD

References